Enorama Pharma AB (ERMA) - Total Liabilities
Based on the latest financial reports, Enorama Pharma AB (ERMA) has total liabilities worth Skr59.58 Million SEK (≈ $6.41 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Enorama Pharma AB - Total Liabilities Trend (2014–2025)
This chart illustrates how Enorama Pharma AB's total liabilities have evolved over time, based on quarterly financial data. See Enorama Pharma AB short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Enorama Pharma AB Competitors by Total Liabilities
The table below lists competitors of Enorama Pharma AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vault Strategic Mining Corp.
V:KNOX
|
Canada | CA$859.97K |
|
Card Factory PLC
LSE:CARD
|
UK | GBX300.10 Million |
|
Fuller Smith & Turner
LSE:FSTA
|
UK | GBX292.50 Million |
|
Elevai Labs, Inc. Common Stock
NASDAQ:ELAB
|
USA | $5.03 Million |
|
Aino Health AB
ST:AINO
|
Sweden | Skr9.57 Million |
|
Omega Therapeutics Inc
NASDAQ:OMGA
|
USA | $141.18 Million |
|
Calidi Biotherapeutics Inc.
NYSE MKT:CLDI
|
USA | $5.10 Million |
|
Zotefoams PLC
LSE:ZTF
|
UK | GBX97.02 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Enorama Pharma AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ERMA market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.63 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Enorama Pharma AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Enorama Pharma AB (2014–2025)
The table below shows the annual total liabilities of Enorama Pharma AB from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr31.71 Million ≈ $3.41 Million |
+291.95% |
| 2024-12-31 | Skr8.09 Million ≈ $870.72K |
-45.50% |
| 2023-12-31 | Skr14.85 Million ≈ $1.60 Million |
-13.67% |
| 2022-12-31 | Skr17.20 Million ≈ $1.85 Million |
-41.86% |
| 2021-12-31 | Skr29.58 Million ≈ $3.18 Million |
-24.40% |
| 2020-12-31 | Skr39.13 Million ≈ $4.21 Million |
+10.52% |
| 2019-12-31 | Skr35.40 Million ≈ $3.81 Million |
+62.33% |
| 2018-12-31 | Skr21.81 Million ≈ $2.35 Million |
+168.41% |
| 2017-12-31 | Skr8.13 Million ≈ $874.50K |
+78.73% |
| 2016-12-31 | Skr4.55 Million ≈ $489.27K |
+71.95% |
| 2015-12-31 | Skr2.64 Million ≈ $284.54K |
+155.71% |
| 2014-12-31 | Skr1.03 Million ≈ $111.27K |
-- |
About Enorama Pharma AB
Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum in Sweden. It offers nicotine chewing gum and nicotine pouches under the NIC-S brand name. The company was incorporated in 2006 and is based in Malmö, Sweden.